Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 10;3(17):2642–2652. doi: 10.1182/bloodadvances.2019000360

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by The American Society of Hematology

PMC Copyright notice

Figure 3. — Depletion of nonmalignant lymphocytes during venetoclax-obinutuzumab treatment. Lymphocyte analysis in PB of patients at baseline (n = 36), after preinduction with obinutuzumab (n = 5), and after 1 year of treatment with venetoclax-obinutuzumab (n = 11) by flow cytometry. Absolute number of B cells (A) and CD4⁺ and CD8⁺ T cells (B) in PB. (C) Absolute number of NK (CD56^bright and CD16⁺) cells in PB (baseline, n = 20). (D) Ratio of CD56^bright (CD56^brightCD16⁻)/CD56^dim (CD56^dimCD16⁺) cells (baseline, n = 6). Horizontal lines indicate reference values. *P < .05, **P < .01, 1-way ANOVA followed by Sidak’s multiple-comparisons test.